Lineage Cell Therapeutics
LCTX
LCTX
123 hedge funds and large institutions have $170M invested in Lineage Cell Therapeutics in 2025 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 29 increasing their positions, 28 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
5.63% more ownership
Funds ownership: 38.5% → 44.14% (+5.6%)
4% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 28
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Holders
123
Holding in Top 10
3
Calls
$180K
Puts
$115K
Top Buyers
| 1 | +$11.8M | |
| 2 | +$2.78M | |
| 3 | +$2.36M | |
| 4 |
Goldman Sachs
New York
|
+$2.24M |
| 5 |
Morgan Stanley
New York
|
+$1.72M |
Top Sellers
| 1 | -$2.73M | |
| 2 | -$986K | |
| 3 | -$588K | |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$530K |
| 5 |
QC
Quadrature Capital
London,
United Kingdom
|
-$257K |
